PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions

@inproceedings{Konecny2016PARPIF,
  title={PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions},
  author={Gottfried E. Konecny and Rebecca S. Kristeleit},
  booktitle={British Journal of Cancer},
  year={2016}
}
Poly(ADP-ribose) polymerase (PARP) inhibitors cause targeted tumour cell death in homologous recombination (HR)-deficient cancers, including BRCA-mutated tumours, by exploiting synthetic lethality. PARP inhibitors are being evaluated in late-stage clinical trials of ovarian cancer (OC). Recently, olaparib was the first PARP inhibitor approved in the European Union and United States for the treatment of advanced BRCA-mutated OC. This paper reviews the role of BRCA mutations for tumorigenesis and… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 10 times over the past 90 days. VIEW TWEETS
31 Citations
137 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 31 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 137 references

Identification of the breast cancer susceptibility gene BRCA 2

  • A Yadav, B Kumar, T Teknos, P Kumar
  • Nature
  • 2011
Highly Influential
6 Excerpts

Similar Papers

Loading similar papers…